<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Russian Journal of Allergy</journal-id><journal-title-group><journal-title xml:lang="en">Russian Journal of Allergy</journal-title><trans-title-group xml:lang="ru"><trans-title>Российский Аллергологический Журнал</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1810-8830</issn><issn publication-format="electronic">2686-682X</issn><publisher><publisher-name xml:lang="en">Publishing House ABV Press</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">686</article-id><article-id pub-id-type="doi">10.36691/RJA686</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Sublingual immunotherapy - questions of efficiency and safety</article-title><trans-title-group xml:lang="ru"><trans-title>Сублингвальная аллерген-специфическая иммунотерапия: вопросы эффективности и безопасности</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Manzhos</surname><given-names>M V</given-names></name><name xml:lang="ru"><surname>Манжос</surname><given-names>М В</given-names></name></name-alternatives><email>mmv_kinel@mail.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Fedenko</surname><given-names>E S</given-names></name><name xml:lang="ru"><surname>Феденко</surname><given-names>Е С</given-names></name></name-alternatives><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name-alternatives><name xml:lang="en"><surname>Myagkova</surname><given-names>M A</given-names></name><name xml:lang="ru"><surname>Мягкова</surname><given-names>М А</given-names></name></name-alternatives><xref ref-type="aff" rid="aff3"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">NOU VPO the medical institute «Reaviz»</institution></aff><aff><institution xml:lang="ru">НОУ ВПО медицинский институт «Реавиз»</institution></aff></aff-alternatives><aff-alternatives id="aff2"><aff><institution xml:lang="en">Institute of Immunology</institution></aff><aff><institution xml:lang="ru">ФГБУ «ГНЦ Институт иммунологии» ФМБА России</institution></aff></aff-alternatives><aff-alternatives id="aff3"><aff><institution xml:lang="en">Institute physiologically active substances of the Russian Academy of Science</institution></aff><aff><institution xml:lang="ru">Институт физиологически активных веществ РАН</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2012-02-15" publication-format="electronic"><day>15</day><month>02</month><year>2012</year></pub-date><volume>9</volume><issue>1</issue><issue-title xml:lang="en">NO1 (2012)</issue-title><issue-title xml:lang="ru">№1 (2012)</issue-title><fpage>12</fpage><lpage>20</lpage><history><date date-type="received" iso-8601-date="2020-03-10"><day>10</day><month>03</month><year>2020</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2012, Pharmarus Print Media</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2012, Фармарус Принт Медиа</copyright-statement><copyright-year>2012</copyright-year><copyright-holder xml:lang="en">Pharmarus Print Media</copyright-holder><copyright-holder xml:lang="ru">Фармарус Принт Медиа</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/" start_date="2014-12-15"/></permissions><self-uri xlink:href="https://rusalljournal.ru/raj/article/view/686">https://rusalljournal.ru/raj/article/view/686</self-uri><abstract xml:lang="en"><p>The basic results of clinical researches on efficacy and safety studying sublingual allergenspecific immunotherapy (slASIT) are presented in the review. The results of SUBLINGUAL application of allergens in Russian Federation are presented.</p></abstract><trans-abstract xml:lang="ru"><p>В обзоре представлены основные результаты клинических исследований по изучению эффективности и безопасности сублингвальной аллерген-специфической иммунотерапии (слАСИТ). Описаны результаты применения пероральных аллергенов в Российской Федерации.</p></trans-abstract><kwd-group xml:lang="en"><kwd>sublingual allergenspecific immunotherapy (slASIT)</kwd><kwd>efficacy</kwd><kwd>safety</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>сублингвальная аллерген-специфическая иммунотерапия</kwd><kwd>эффективность</kwd><kwd>безопасность</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Гущин И.С. Физиология иммунитета и аллергия. Физиология и патология иммунной системы. 2004, № 9, с. 17-20.</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Black J.H. The oral administration of pollen. J. Lab. Clin. Med. 1927, v. 12, p. 1156.</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Morris D. Use of sublingual antigen in diagnosis and treatment of food allergy. Ann. Allergy. 1969, v. 27 (6), p. 289-294.</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Penagos M., Passalacqua G., Compalati E. et al. Meta-analysis of the efficacy of sublingual immunotherapy in allergic asthma in pediatric patient 3 to 18 years of age. Chest. 2008, v. 133, p. 599-609.</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Scadding K., Brostoff J. Low dose sublingual therapy in patients with allergic rhinitis due to dust mite. Clin. Allergy, 1986, v. 16, p. 483-491.</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Tari M.G., Mancino M., Monti G. Efficacy of sublingual immunotherapy in patients with rhinitis and asthma due to house dust mite. A double blind study. Allergol. Immunopathol. 1990, v. 18 (5), p. 277-284.</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Passalacqua, Giovanni et al. Randomized controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced. The Lancet. 1998, v. 351, p. 629-632.</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Malling H., Weeke B. et al. Immunotherapy. Position Paper of the European Academy of Allergy and Clinical Immunology Allergy. 1993, v. 48 (14), p. 9-35.</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Bousquet J., Lockey R., Malling H.J. et al. World Health Organization Position Paper. Allergen immunotherapy: therapeutic vaccines for allergic diseases. Allergy. 1998, v. 53, p. 1-42.</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Malling H.J., Abreu-Nogueira J., Alvarez-Cuesta E. et al. EAACI Position Paper on local immunotherapy. Allergy. 1998, v. 53, p. 933-944.</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Bousquet J., Van Cauwenberge P. et al. Allergic rhinitis and its impact on asthma. J. Allergy Clin. Immunol. 2001, v. 108, suppl. 5, p. 147-334.</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Bousquet J., Khaltaev N., Cruz A.A. et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen) Ed. Allergy. 2008, v. 63, suppl. 86, p. 8-160.</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Canonica G.W., Bousquet J., Casale T. et al. Sub-Lingual Immunotherapy: World Allergy Organization Position Paper 2009. World Allergy Organization Journal: November 2009, v. 2, p. 233-281.</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Coifman R.E., Cox L.S. 2006 American Academy of Allergy, Asthma &amp; Immunology member immunotherapy practice patterns and concerns. J. Allergy Clin. Immunol. 2007, v. 119, p. 1012-1013.</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Cox L. Sublingual immunotherapy and allergic rhinitis. Curr. Allergy Asthma. 2008, Rep. 8 (2), p. 102-110.</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Madonini E., Agostinis F., Barra R. et al. Long-term and preventive effects of sublingual allergen-specific immunotherapy: a retrospective, multicentre study. Int. J. Immunopathol Pharmacol. 2003, v. 16 (l), p. 73-79.</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Novembre E., Galli E. et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 2004, v. 114 (4), p. 851-857.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Moingeon P., Batard T, Fadel R. et al. Immune mechanisms of allergen-specific sublingual immunotherapy. Allergy. 2006, v. 61, p. 151-165.</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Pajno G., Vita D., Parmiani S. et al. Impact of sublingual immunotherapy on seasonal asthma and skin reactivity in children allergic to Parietaria pollen treated with inhaled fluticasone propionate. Clin. Exp. Allergy. 2003, v. 33, p. 1641-1647.</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Stelmach I., Kaczmarek-Wozniak J., Majak P. et al. Efficacy and safety of high-doses sublingual immunotherapy in ultrarush scheme in children allergic to grass pollen. Clin. Exp. Allergy. 2009, v. 39, p. 401-408.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Mortemousque B., Bertel F., De Casamayor J. et al. House dust mite sublingualswallow immunotherapy in perennial conjunctivitis: a double-blind, placebo-controlled study. Clin. Exp. Allergy. 2003, v. 33, p. 464-469.</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Passalacqua G., Pawankar R., Baena-Cagnani C., Canonica G. Sublingual immunotherapy: where do we stand? Present and future. Curr. Opin. Allergy Clin. Immunol. 2009, v. 9, p. 1-3.</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Canonica G.W, Baena Cagnani C., Bousquet J. et al. Recommendations for standardization of clinical trials with Allergen Specific Immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy. 2007, v. 62, p. 317-324.</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Wilson A.M., O’Byrne P.M., Parameswaran K. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am. J. Med. 2004, v. 116, p. 338-344.</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Marcucci F., Sensi L., Di Cara G. et al. Dose dependence of immunological response to sublingual immunotherapy Allergy 2005, v. 60, p. 952-956.</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Calderon M.A., Rak S., Durham S.R. Grass Pollen Tablets for Sublingual Immunotherapy in seasonal allergic rhinitis. AAAAI. 2005, v. 115, p. 65.</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Calamita Z., Saconato H., Pela A.B., Atallah A.N. Efficacy of sublingual immunotherapy in asthma: systematic review of randomized clinical trials using the Cochrane collaboration method. Allergy. 2006, v. 61, p. 1162-1172.</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Olaguibel J.M., Alvarez Puebla M.J. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. J. Investig. Allergol Clin. Immunol. 2005, v. 15 (1), p. 9-16.</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Wilson D.R., Lima M.I., Durham S.R. Sublingual immunotherapy for allergic rhinitis: systematic review and metaanalysis. Allergy. 2005, v. 60 (l), p. 4-12.</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Penagos M., Compalati E., Tarantini F. et al. Efficacy of sublingual immunotherapy in the treatment of allergic rhinitis in pediatric patients 3 to 18 years of age: a meta-analysis of randomized, placebo-controlled, double-blind trials. Ann. Allergy Asthma Immunol. 2006, v. 97 (2), p. 141-148.</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Malling H.J. Is sublingual immunotherapy clinically effective? Curr. Opin. Allergy Clin. Immunol. 2002, v. 2 (6), p. 523-531.</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>Nieto A., Mazon A., Pamies R. et al. Sublingual immunotherapy for allergic respiratory diseases: An evaluation of meta-analyses. J. Allergy Clin. Immunol. 2009, v. 124 (1), p. 157-161.</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Quirino T, Iemoli E., Siciliani E. et al. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double-blind double-dummy study. Clin. Exp. Allergy. 1996, v. 26, p. 1253-1261.</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Mungan D., Misirligil Z., Gurbuz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite sensitive patients with rhinitis and asthma: a placebocontrolled study. Ann. Allergy Asthma Immunol. 1999, v. 82, p. 485-490.</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Khinchi M.S., Poulsen L.K., Carat F. et al. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, doubleblind, double-dummy study. Allergy. 2004, v 59 (1), p. 45-53.</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Passalacqua G., Canonica G.W Sublingual or injection immunotherapy: the final answer? Allergy. 2004, v. 59 (3), p. 37-38.</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Della Volpe A., DAgostino G.W., Varricchio A.M. et al. Sublingual allergen-specific immunotherapy in allergic rhinitis and related pathologies: Efficacy in a paediatric population. Int. J. Immunopathol. Pharmacol. 2002, v. 15 (l), p. 35-40.</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Михайлов Е.Л. Пероральная специфическая гипосенсибилизация амброзийного поллиноза. Автореф. диссертации канд. мед. наук. М., 1978, 20 с.</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Roder E., Berger M.Y., Hop W.C. et al. Sublingual immunotherapy with grass pollen is not effective in symptomatic youngsters in primary care. J. Allergy Clin. Immunol. 2007, v. 119, p. 892-898.</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Reider N. Sublingual immunotherapy for allergic rhinoconjunctivitis — the seeming and the real. Int. Arch. Allergy Immunol. 2005, v. 137 (3), p. 181-186.</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Bufe A., Ziegler-Kirbach E., Stoeckmann E. et al. Efficacy of sublingual swallow immunotherapy in children with severe grass pollen allergic symptoms: a double-blind placebo-controlled study. Allergy. 2004, v. 59 (5), p. 498-504.</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Ricardo J.S., Lozano A., Caceres M.E. et al. Allergen immunotherapy for prevention and treatment of respiratory allergy in childhood. Arch. argent. pediatr. 2010, v 108 (3), p. 258-265.</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Курбачева О.М. Сублингвальная аллерген-специфическая иммунотерапия — метод системного лечения атопических заболеваний. Рос. Аллергол. Журн. 2006, № 6, с. 3-9.</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Pajno G.B., Passalacqua G., Vita D. et al. Sublingual immunotherapy abrogates seasonal bronchial hyperresponsiveness in children with Parietaria — induced respiratory allergy: a randomized controlled trial. Allergy. 2004, v. 59 (8), p. 883-887.</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Marogna M., Spadolini I., MIassolo A. et al. Clinical, functional, and immunologic effects of sublingual immunotherapy in birch pollinosis: a 3-year randomized controlled study. J. Allergy Clin. Immunol. 2005, v. 15 (6), p. 1184-1188.</mixed-citation></ref><ref id="B46"><label>46.</label><mixed-citation>De Groot H., Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy. 2009, v. 64, p. 963-964.</mixed-citation></ref><ref id="B47"><label>47.</label><mixed-citation>Stewart G.E., Lockey R.F. Systemic reactions from allergen immunotherapy. J. Allergy Clin. Immunol. 1992, v. 90, p. 567-578.</mixed-citation></ref><ref id="B48"><label>48.</label><mixed-citation>Amin H.S., Liss G.M., Bernstein D.I. Evaluation ofnear-fatal reactions to allergen immunotherapy injections. J. Allergy Clin. Immunol. 2006, v. 117, p. 169-175.</mixed-citation></ref><ref id="B49"><label>49.</label><mixed-citation>Andre C., Vatrinet C. et al. Safety of sublingual-swallow immunotherapy in children and adults. Int. Arch. Allergy Immunol. 2000, v. 121 (3), p. 229-234.</mixed-citation></ref><ref id="B50"><label>50.</label><mixed-citation>Agostinis F., Foglia C., Landi M. et al. The safety of sublingual immunotherapy with one or multiple pollen allergens in children. Allergy. 2008, v. 63, p. 1637-1639.</mixed-citation></ref><ref id="B51"><label>51.</label><mixed-citation>Lombardi C., Gargioni S., Cottini M. et al. The safety of sublingual immunotherapy with one or more allergens in adults. Allergy. 2008, v. 63, p. 375-376.</mixed-citation></ref><ref id="B52"><label>52.</label><mixed-citation>Gidaro G.B., Marcucci F., Sensi L. et al. The safety of sublin-gual-swallow immunotherapy: an analysis of published studies. Clin. Exp. Allergy. 2005, v. 35 (5), p. 565-571.</mixed-citation></ref><ref id="B53"><label>53.</label><mixed-citation>Gammeri E., Arena A., D’Anneo R. et al. Safety and toler-ability of ultra-rush (20minutes) sublingual immunotherapy in patients with allergic rhinitis and/or asthma. Allergol. Imrnimopathol. 2005, v. 33 (4), p. 221-223.</mixed-citation></ref><ref id="B54"><label>54.</label><mixed-citation>Балаболкин И.И., Кувшинова Е.Д., Ксензова Л.Д. и соавт. Эффективность сублингвальной аллерген-специфичес-кой иммунотерапии детей, страдающих поллинозами. Аллергология и иммунология. 2001, № 2, с. 171-174.</mixed-citation></ref><ref id="B55"><label>55.</label><mixed-citation>Передкова Е.В., Медуницин Н.В., Порошина Ю.А. Пероральный метод специфической иммунотерапии поллинозов. Иммунология. 1986, № 6, с. 49-51.</mixed-citation></ref><ref id="B56"><label>56.</label><mixed-citation>Смолкин Ю.С., Ветров В.П., Страхова М.С. Иммунотерапия при атопических заболеваниях у детей. Рос. медиц. журн. 1998, № 6, с. 50-54.</mixed-citation></ref><ref id="B57"><label>57.</label><mixed-citation>Радунская С.Ф., Лавренчик Е.И., Михеева Г. Н., Балаболкин И.И. и соавт. Результаты применения в РФ пе-роральных аллергенов фирмы «Sevac» («СЕВАФАРМА», Чехия) для специфической иммунотерапии поллинозов. Сб. научн. трудов «Современные проблемы аллергологии, клинической иммунологии и иммунофармакологии», М., 1998, с. 711.</mixed-citation></ref><ref id="B58"><label>58.</label><mixed-citation>Ревякина В.А., Арсентьева Н.А., Филатова Т.А. Эффективность аллерген-специфической иммунотерапии пероральными аллергенами «Весенняя смесь ранняя» у детей с поллинозом. Рос. Аллергол. Журн. 2007, № 2, с. 63-67.</mixed-citation></ref><ref id="B59"><label>59.</label><mixed-citation>Манжос М.В., Феденко Е.С., Мягкова М.А. и соавт. Клиническая эффективность различных схем сублингвальной аллерген-специфической иммунотерапии при поллинозе. Рос. Аллергол. Журн. 2008, № 3, с. 27-31.</mixed-citation></ref><ref id="B60"><label>60.</label><mixed-citation>Горячкина Л.А., Ненашева Н.М., Дробик О.С., Бжедуго-ва Е.З. Локальная аллерген-специфическая иммунотерапия. Пособие для врачей. М., 2008, 34 с.</mixed-citation></ref></ref-list></back></article>
